- |||||||||| B002 / Shanghai Pharma
Trial completion, Trial completion date, Trial primary completion date, Metastases: B002-101: B002 in Patients With HER2-positive Breast Cancer (clinicaltrials.gov) - Mar 24, 2023
P1, N=23, Completed,
Recruiting --> Completed | Trial completion date: Jul 2023 --> Apr 2022 | Trial primary completion date: Feb 2023 --> Apr 2022
- |||||||||| B002 / Shanghai Pharma
Trial completion date, Trial primary completion date, Metastases: B002-101: B002 in Patients With HER2-positive Breast Cancer (clinicaltrials.gov) - Oct 21, 2022
P1, N=19, Recruiting,
Recruiting --> Completed | Trial completion date: Jul 2023 --> Apr 2022 | Trial primary completion date: Feb 2023 --> Apr 2022 Trial completion date: Dec 2022 --> Jul 2023 | Trial primary completion date: Sep 2022 --> Dec 2022
- |||||||||| B002 / Shanghai Pharma
Trial completion date, Trial primary completion date, Metastases: B002-101: B002 in Patients With HER2-positive Breast Cancer (clinicaltrials.gov) - Aug 1, 2022
P1, N=19, Recruiting,
Trial completion date: Dec 2022 --> Jul 2023 | Trial primary completion date: Sep 2022 --> Dec 2022 Trial completion date: Mar 2021 --> Dec 2022 | Trial primary completion date: Sep 2020 --> Sep 2022
- |||||||||| B002 / Shanghai Pharma
Trial primary completion date, Metastases: B002-101: B002 in Patients With HER2-positive Breast Cancer (clinicaltrials.gov) - Jul 10, 2020
P1, N=19, Recruiting,
Trial completion date: Mar 2021 --> Dec 2022 | Trial primary completion date: Sep 2020 --> Sep 2022 Trial primary completion date: May 2020 --> Sep 2020
|
